ABSTRACT
Polycystic ovary syndrome [PCOS] is a common endocrine / metabolic disorder in women of reproductive age .Abdominal adiposity and obesity are frequently present in PCOS. It now appears that, obesity is associated with a low-grade inflammation of white adipose tissue. Adipokines play a significant role in the pathogenesis of a low-grade inflammation associated with obesity. Among variety of adipokines, resistin and visfatin are proposed as important pro inflammatory mediators and they have recently been suggested to be associated with obesity related diseases. The aim of this study is to evaluate the correlation of visfatin and resistin serum levels and the ratio of these two adipokines with BMI in PCOS women under age of 35 years old. Twenty eight young women with clinically confirmed PCOS disease [14 lean and 14 obese], and 12 young, healthy and lean women with stable weight and BMI<25 were enrolled. Blood was obtained from the included persons, and visfatin and resistin were assessed by ELISA method. We did not observe any significant differences in serum visfatin and resistin concentrations and also in the Visfatin/Resistin ratio between PCOS and control group. Also we did not found a significant correlation between visfatin and resistin with BMI. This study demonstrated that serum resistin and visfatin levels do not seem to be directly involved in the pathology of PCOS
ABSTRACT
Perforin[p] is the primary mediator of short term cytotoxicity, it is accumulated in response to proinflammatory cytokines and stored in T lymphocyte, NK cells and NKT cells are released upon activation. Perforin is a prototypical cytotoxic molecule involved in cell mediated immunity against various pathogens, alloantigens and particularly different tumors.The purpose of this study was to determine perforin level in prostate cancer [P.Ca] and Benign Prostatic Hyperplasia [BPH] This is study was performed on 59 patients consisting of 28 patients with P.Ca and 31 patients with BPH.Perforin and PSA levels were measured in cancer and BPH patients using ELISA method. Mean Perforin value was significantly lower in P.Ca patients than in BPH patients [p < 0.01] where as mean serum PSA level was significantly higher in the cancer patients in comparison to the BPH group [P < 0.01 Our finding indicate probability of problem in expression of cytotoxic molecule ,perforin in and around the tumor
ABSTRACT
Determination of certain biochemical parameters in hyperlipemic speciemens causes problems, which is due to interference of lipids. Lipid extraction using ultracentrifuge is expensive and is not always available. Another method of lipid extraction is by using ethylacetate; thus, we compared certain biochemical parameter values in lipemic specimens and in the same samples after lipid extraction with ethylacetate. In this experimental study, 45 normal serum samples were selected. To obtain lipemic specimens, lipid was added to these samples. Each serum sample was then divided into two aliquots; in one sample lipid was extracted using ethylacetate while in the other one ultracentrifugation was used. Later, 13 biochemical parameters were determined in these lipid free samples and their results were compared using paired samples t-Test. While the biochemical parameters of the samples were normal at the beginning, they were measured as abnormal after lipid addition. There were no significant difference between values obtained by ethylacetate extraction method and standard ultracentrifugation method [P<0.6]. Although urea value was lower and ALT was higher in ethylacetate extraction method, their values were closer to the original specimen compared to ultracentrifuge. It seems that extraction of lipids from lipemic speciemens using ethylacetate is a feasible method; however, further studies regarding this issue is recommended
ABSTRACT
Our aim was to determine a more predictive cut-off value for free to total prostate-specific antigen ratio [f/tPSA] to better differentiate prostate cancer [PCa] from benign prostate hyperplasia [BPH] in Iranian patients with serum PSA levels between 4 and 20 ng/mL. This study was performed on 332 men with serum tPSA level of 4 to 20 ng/mL. All patients underwent transrectal ultrasound guided biopsies. Serum levels of tPSA and fPSA were measured by Roche immunoassay Elecsys 2010. Relationship between f/tPSA and cases of PCa was determined. Prostate cancer detected in 49 [15%] patients. Incidence of PCa for serum tPSA level < l0ng/mL and serum tPSA level of 10.1 to 20 ng/ mL was 17 [6.7%] and 32 [39.5%], respectively. Mean f/tPSA value was significantly lower in PCa patients [0.12 +/- 0.01] than in benign histology group [0.16 +/- 0.03]. Among patients with serum PSA level of 4 to 10 ng/mL [n = 251], mean f/tPSA in benign histology group [n = 234] was 0.16 +/- 0.08 and in PCa group [n = 17] was 0.13 +/- 0.06 [P < .05]. For serum PSA level of 10.1 to 20 ng/mL [n = 81], mean f/tPSA in benign histology group [n = 49] was 0.16 +/- 0.08 and in PCa group [n = 32] was 0.12 +/- 0.05 [P < .05]. The cut-off value of 0.12 produced 76% sensitivity and 71% specificity, whereas the cut-off value of 0.14 yielded 83.5% sensitivity and 61% specificity. Determination of f/tPSA ratio improves differentiation of Pea from BPH. We recommend a cut-off value of 0.14 to be applied to Iranian patients